Positive Phase III Ustekinumab Data Puts Samsung Bioepis In The Race
Korean Biosimilars Developer Shares Data For Sandoz-Partnered Stelara Biosimilar
Samsung Bioepis has welcomed positive six-month Phase III data for its SB17 proposed biosimilar to Stelara, the fourth candidate in the company’s immunology pipeline.
